<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131177" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oncocytic (H&#x000fc;rthle Cell) Thyroid Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariduddin</surname>
            <given-names>Maria M.</given-names>
          </name>
          <aff>MD at Home</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sherman</surname>
            <given-names>Samantha</given-names>
          </name>
          <aff>Albany Medical College, Albany, NY</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Menon</surname>
            <given-names>Gopal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Wajihuddin</given-names>
          </name>
          <aff>Franciscan Health Crown Point</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Fariduddin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samantha Sherman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gopal Menon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Wajihuddin Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131177.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Oncocytic (H&#x000fc;rthle cell) thyroid carcinoma is a rare subtype of thyroid cancer that originates from oncocytic cells, a specialized type of follicular thyroid cell characterized by its eosinophilic and granular cytoplasm. Previously classified as a variant of follicular thyroid carcinoma, the World Health Organization redefined oncocytic thyroid carcinoma due to its unique histopathological and molecular features.</p>
        <p>Oncocytic carcinoma typically presents as a thyroid nodule, often occurring in middle-aged women. However, the clinical features of this disease process vary, ranging from an asymptomatic clinical course to symptoms such as dysphagia, voice changes, or hoarseness due to local invasion. Diagnosis involves thyroid ultrasonography and fine-needle aspiration, with molecular testing sometimes used to evaluate lesions further.&#x000a0;</p>
        <p>Treatment typically involves total thyroidectomy, particularly for more extensive or invasive tumors, as radioactive iodine therapy is less effective for this cancer. The prognosis of&#x000a0;oncocytic thyroid carcinoma is generally favorable with early diagnosis and treatment but declines significantly with advanced disease, larger tumor size, or metastasis. Lifelong monitoring for recurrence is essential, and complications from the disease and its treatment can impact quality of life.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence in the early recognition of oncocytic thyroid carcinoma's clinical features, performing the recommended evaluation, and implementing an appropriate interprofessional management approach to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features of oncocytic thyroid cancer.</p></list-item><list-item><p>Assess the histological characteristics of&#x000a0;oncocytic&#x000a0;carcinomas of the thyroid.</p></list-item><list-item><p>Evaluate the treatment options for&#x000a0;oncocytic thyroid cancer.</p></list-item><list-item><p>Apply interprofessional team strategies to improve care coordination and outcomes in patients&#x000a0;with oncocytic thyroid cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131177&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131177">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131177.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Oncocytic carcinoma, previously known as H&#x000fc;rthle cell carcinoma, is a rare type of thyroid cancer originating from oncocytic cells, a specialized type of follicular thyroid cell. These cells are identified by their eosinophilic cytoplasm and an abundance of granular cytoplasm. Until 2022, oncocytic carcinoma was considered a variant of follicular thyroid carcinoma, but it has since been reclassified as a separate subtype by the World Health Organization (WHO). Oncocytic thyroid carcinoma's distinct histopathological features and molecular differences, particularly mutations in the mitochondrial genome and gene expression profiles, set it apart from follicular thyroid carcinoma.<xref ref-type="bibr" rid="article-131177.r1">[1]</xref></p>
        <p>Similar to other types of thyroid cancer, oncocytic carcinoma often occurs in middle-aged women as a thyroid nodule, which may not cause symptoms. Diagnosis is typically made through thyroid ultrasonography and fine-needle aspiration or core needle biopsy of the nodule. Staging oncocytic carcinoma through imaging studies may be necessary due to its increased tendency for metastatic disease. The treatment for localized oncocytic carcinoma is thyroidectomy. Unlike other types of thyroid cancer, oncocytic carcinoma has a lower tendency for radioactive iodine uptake, so this is often not a treatment option. However, newer treatments, such as tyrosine kinase inhibitors, may be considered.</p>
        <p>Treatment options continue to evolve as our knowledge of molecular markers grows, and more targeted agents become available. Due to the rarity and unique characteristics of oncocytic thyroid carcinoma, an extensive understanding of its pathophysiology, epidemiology, and optimal management strategies is essential to improving patient outcomes and guiding effective therapeutic interventions.</p>
      </sec>
      <sec id="article-131177.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Various genetic, environmental, and biological factors influence the development of oncocytic thyroid cancer. This type of cancer originates from specialized follicular thyroid cells called oncocytes, characterized by their abundant eosinophilic cytoplasm and high mitochondrial content. The pathogenesis of oncocytic cancer is associated with specific genetic mutations, particularly in mitochondrial DNA, and changes in nuclear genes. Mutations in oncogenes like<italic toggle="yes"> BRAF</italic> and <italic toggle="yes">HRAS</italic> and inactivation of tumor suppressor genes (eg,&#x000a0;<italic toggle="yes">PTEN)</italic>&#x000a0;have been identified, indicating a disruption of normal cellular signaling pathways that control cell growth and survival.<xref ref-type="bibr" rid="article-131177.r2">[2]</xref></p>
        <p>Environmental factors also play a significant role in the development of oncocytic thyroid carcinoma. Exposure to ionizing radiation, especially during childhood, has been established as a risk factor for various thyroid malignancies, including oncocytic carcinoma. Individuals with preexisting thyroid conditions, such as adenomas or goiter, may have an elevated risk of developing oncocytic cancer. Additionally, genetic syndromes, including multiple endocrine neoplasia type 1 (MEN 1) and familial nonmedullary thyroid cancer, have been associated with an increased incidence of oncocytic carcinoma.<xref ref-type="bibr" rid="article-131177.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-131177.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence and prevalence of oncocytic carcinoma are less extensively documented in comparison to more prevalent thyroid cancers such as papillary or follicular thyroid carcinoma. This is in part due to its recent identification as a distinct entity. Oncocytic thyroid cancer accounts for approximately 3% to 4% of all thyroid malignancies.<xref ref-type="bibr" rid="article-131177.r4">[4]</xref></p>
        <p>Oncocytic carcinoma is more commonly diagnosed in women, with a ratio of approximately 1.6 to 4.8:1 compared to men, and typically affects middle-aged adults, particularly those aged between 50 and 60 years. Specific populations, particularly those in areas with endemic goiter or iodine deficiency, may exhibit higher rates of oncocytic carcinoma.<xref ref-type="bibr" rid="article-131177.r4">[4]</xref></p>
        <p>Despite its lower incidence compared to other forms of thyroid cancer, the aggressive nature and tendency of oncocytic carcinoma to metastasize contribute to its clinical significance. The 5-year relative survival rates for oncocytic carcinoma can vary widely, influenced by factors including tumor stage, histological characteristics, and the presence of metastases at diagnosis. The overall 5-year relative survival rate is high, with a weighted average of all stages of the disease at 98.5%. Approximately 2100 thyroid cancer deaths occur per year in the United States.<xref ref-type="bibr" rid="article-131177.r5">[5]</xref>&#x000a0;Understanding the epidemiological patterns of oncocytic carcinoma is crucial for identifying at-risk populations and informing screening and management strategies.</p>
      </sec>
      <sec id="article-131177.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of oncocytic thyroid cancer entails a complex interplay of genetic, molecular, and cellular mechanisms contributing to its distinct behavior and clinical presentation. Oncocytic thyroid cancer originates from oncocytic cells, variants of follicular thyroid cells distinguished by abundant eosinophilic cytoplasm, high mitochondrial content, and atypical morphology. Consequently, oncocytic thyroid cancer is associated with significant genetic alterations.<xref ref-type="bibr" rid="article-131177.r2">[2]</xref></p>
        <p>The cancer is linked to changes in the mitochondria, driven by mutations in mitochondrial DNA (mtDNA), including small mutations and larger deletions, leading to compromised energy production and subsequent compensatory mitochondrial proliferation within the cell.<xref ref-type="bibr" rid="article-131177.r6">[6]</xref> Furthermore, oncocytic tumors exhibit specific alterations in nuclear DNA, although these are less prevalent compared to other thyroid tumors. For instance, mutations in oncogenes like <italic toggle="yes">HRAS</italic> and <italic toggle="yes">BRAF</italic>, commonly observed in other types of thyroid cancer, are rare in oncocytic tumors.<xref ref-type="bibr" rid="article-131177.r7">[7]</xref></p>
        <p>Histopathologically, oncocytic carcinoma is distinguished by a high density of oncocytic cells, often accompanied by vascular invasion and a tendency for extra-thyroidal extension. Thyroid tumors are classified as oncocytic neoplasms when more than 75% of the tumor comprises oncocytic cells.<xref ref-type="bibr" rid="article-131177.r8">[8]</xref> This aggressive behavior stems partly from the tumor's capacity to invade surrounding tissues and metastasize to distant sites such as the lungs and bones.<xref ref-type="bibr" rid="article-131177.r9">[9]</xref> The vascularization of the tumor microenvironment is also crucial, as increased angiogenesis supports the tumor's growth and survival.</p>
      </sec>
      <sec id="article-131177.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Oncocytic carcinoma is histologically characterized by at least 75% oncocytes, distinguished by their large size and well-defined cell borders.<xref ref-type="bibr" rid="article-131177.r2">[2]</xref> The tumor cells display deeply eosinophilic and granular cytoplasm, large nuclei with prominent nucleoli, and a complete loss of cell polarity (see <bold>Image</bold>. Oncocytic Thyroid Carcinoma). Growth patterns may vary, presenting as follicular, trabecular, solid, or papillary formations. Occasional nuclear grooves or pseudo-inclusions can be observed. Additionally, psammomatous-like calcifications may be present in the lumen of follicles. However, unlike in papillary carcinoma, these calcifications lack the laminated structure typically seen in psammoma bodies within the stroma. Malignant oncocytic carcinoma typically exhibits a thicker capsule than adenomas, a solid or trabecular growth pattern, smaller cells with a high nuclear-to-cytoplasmic ratio, and increased mitotic figures. Poorly differentiated tumors are characterized by a size &#x0003e;4 cm, tumor necrosis, numerous mitoses, and foci of small tumor cells.<xref ref-type="bibr" rid="article-131177.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-131177.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Oncocytic thyroid cancers present similarly to other differentiated thyroid cancers. Patients often present with an asymptomatic thyroid nodule that is incidentally detected during imaging. Symptoms, when present, may include a palpable nodule that has grown over time, dysphagia, voice changes, or signs of recurrent laryngeal nerve injury such as hoarseness. Given the higher likelihood of distant metastases, particularly to the lungs and bones, clinicians should assess for bone pain and new respiratory symptoms.</p>
        <p>A comprehensive physical examination should focus on the thyroid gland and cervical lymph nodes. Clinicians should inquire about any previous exposure to radiation, particularly to the head and neck, during childhood, as this is a known risk factor for thyroid malignancies. Family history, including multiple endocrine neoplasia (MEN) and other thyroid cancers, should be discussed, as this may predispose individuals to oncocytic carcinoma.</p>
      </sec>
      <sec id="article-131177.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients presenting with thyroid nodules should have thyroid function tests performed at baseline, even though cancers are not hormonally active. A thyroid ultrasound is the initial imaging test of choice. Image-guided fine or core needle biopsies can identify oncocytic thyroid lesions, typically reported as Bethesda 4 lesions. However, needle biopsies cannot make this distinction because the demonstration of capsular and vascular invasion is the most reliable means of distinguishing between adenomas and invasive oncocytic carcinomas.&#x000a0;</p>
        <p>Molecular testing with commercially available genetic testing kits (eg, Afirma<sup>&#x000ae;</sup> or ThyroSeq<sup>&#x000ae;</sup>&#x000a0;Genetic Classifier) may be helpful in further evaluating Bethesda 3 and 4 lesions. However, the data on their efficacy in oncocytic carcinoma are limited, and thus far, they have been associated with high false-positive rates (38% to 41%), which limits their utility.<xref ref-type="bibr" rid="article-131177.r10">[10]</xref><xref ref-type="bibr" rid="article-131177.r11">[11]</xref> Ultimately, most patients with oncocytic lesions undergo a diagnostic thyroid lobectomy. On final pathology, the diagnosis of oncocytic thyroid carcinoma can be made.</p>
        <p>Patients with clinical features suspicious of high-risk or locally advanced disease, including ultrasound imaging indicating extrathyroidal extension or local invasion, clinical lymphadenopathy, or symptoms of local invasion, including hoarseness, dysphagia, or stridor, should undergo further evaluation. Cervical ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) may be used to stage the disease. If distant metastatic disease is suspected, whole-body&#x000a0;positron emission tomography (PET)/CT and bone scans are valuable modalities.&#x000a0;Thyroid uptake studies are generally less helpful for oncocytic tumors, as they do not reliably absorb radioactive iodine.<xref ref-type="bibr" rid="article-131177.r12">[12]</xref></p>
      </sec>
      <sec id="article-131177.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>The primary treatment for oncocytic thyroid cancer is thyroidectomy, with the specific approach contingent upon the tumor's size, location, and potential metastasis. Total thyroidectomy, involving the complete removal of the thyroid gland, is the most frequently performed procedure. This procedure is recommended for patients with tumors exceeding 4 cm, those displaying invasive characteristics, or in cases where lymph node metastasis is suspected.<xref ref-type="bibr" rid="article-131177.r4">[4]</xref> Total thyroidectomy diminishes the risk of recurrence and enables the postoperative monitoring of thyroglobulin levels, a critical marker for oncocytic carcinoma recurrence.</p>
        <p>Thyroid lobectomy is recommended in cases where the cytology suggests a Bethesda 3 or 4 lesion.<xref ref-type="bibr" rid="article-131177.r12">[12]</xref>&#x000a0;This procedure also serves a diagnostic purpose, and if the lobectomy specimen indicates oncocytic thyroid carcinoma, a completion thyroidectomy is advised. In certain instances where the tumor is small and confined to 1 lobe of the thyroid, a lobectomy (removal of 1 lobe) may be considered. Nevertheless, due to the aggressive nature of oncocytic carcinoma and the potential for multifocality, total thyroidectomy is often the preferred option.</p>
        <p>Additionally, therapeutic neck dissection of the central and lateral compartments should be performed for clinically positive lymph nodes.<xref ref-type="bibr" rid="article-131177.r12">[12]</xref>&#x000a0;</p>
        <p>
<bold>Medical Treatment</bold>
</p>
        <p>After total thyroidectomy, patients require thyroid hormone replacement, usually with levothyroxine. Levothyroxine is dosed to suppress thyroid-stimulating hormone (TSH) production, potentially reducing the risk of residual cancer growth. The degree of TSH suppression is based on the risk of tumor recurrence.&#x000a0;</p>
        <p>Currently, guidelines regarding the postoperative use of radioactive iodine (RAI) are inconsistent. The largest study to date found no improvement in disease-specific or overall survival with the addition of RAI to surgery, even in patients at high risk for recurrence. Occasionally, patients have tumors that concentrate iodine. RAI may be applicable in these patients, and a sodium iodide I 123 or I 131 uptake study can help identify patients who are candidates for ablation.&#x000a0;</p>
        <p>For patients with metastatic oncocytic carcinoma who are asymptomatic and have well-differentiated tumors with slow-growing disease, observation is an acceptable option as long as they do not have brain metastases. However, for patients with symptoms or rapidly growing metastatic tumors that respond to iodine treatment, RAI is a preferable option. If the patient's tumor is not suitable for RAI, systemic therapy with tyrosine kinase inhibitors (eg, lenvatinib or sorafenib) is considered.<xref ref-type="bibr" rid="article-131177.r13">[13]</xref><xref ref-type="bibr" rid="article-131177.r14">[14]</xref> Lenvatinib is preferred over sorafenib due to its better adverse effect profile. However, because oncocytic cell tumors are rare, most of the data for using tyrosine kinase inhibitors in metastatic disease is extrapolated from other thyroid carcinomas.<xref ref-type="bibr" rid="article-131177.r12">[12]</xref></p>
        <p>The molecular analysis of these cancers can be beneficial. Larotrectinib or entrectinib can be used for cancers with neurotrophic tyrosine receptor kinase (<italic toggle="yes">NTRK</italic>) fusion, and pembrolizumab can be used for patients with a high tumor mutation burden, regardless of the cancer type.<xref ref-type="bibr" rid="article-131177.r15">[15]</xref><xref ref-type="bibr" rid="article-131177.r16">[16]</xref>&#x000a0;Selpercatinib and pralsetinib are helpful for patients with non-small cell lung cancers and thyroid carcinomas with <italic toggle="yes">RET</italic> fusions and can be used as a first-line treatment for patients with this mutation.<xref ref-type="bibr" rid="article-131177.r17">[17]</xref><xref ref-type="bibr" rid="article-131177.r18">[18]</xref><xref ref-type="bibr" rid="article-131177.r19">[19]</xref> Most patients with <italic toggle="yes">RET</italic> fusions have medullary thyroid carcinoma, but the findings can be applied to oncocytic thyroid carcinomas with <italic toggle="yes">RET</italic> fusions. While cytotoxic chemotherapy has been used in small studies, it has not been shown to benefit patients with oncocytic carcinoma significantly and is typically used as a last resort.<xref ref-type="bibr" rid="article-131177.r20">[20]</xref></p>
        <p>
<bold>Radiation Treatment</bold>
</p>
        <p>If surgical resection is not possible or contraindicated, particularly if the cancer has spread beyond the thyroid and threatens vital structures, then external beam radiation therapy or intensity-modulated radiation therapy can be considered.<xref ref-type="bibr" rid="article-131177.r21">[21]</xref><xref ref-type="bibr" rid="article-131177.r22">[22]</xref><xref ref-type="bibr" rid="article-131177.r23">[23]</xref><xref ref-type="bibr" rid="article-131177.r2">[2]</xref></p>
        <p>
<bold>Monitoring and Follow-Up</bold>
</p>
        <p>Regular follow-up care is crucial for patients treated for oncocytic carcinoma. This typically includes physical examinations, neck ultrasounds, and monitoring of serum thyroglobulin levels. Patients should be educated about the signs of recurrence, eg, new lumps in the neck or voice changes. The frequency and type of follow-up imaging and laboratory testing will depend on individual risk factors and the initial treatment approach.</p>
      </sec>
      <sec id="article-131177.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses that should be considered when evaluating&#x000a0;oncocytic thyroid cancer include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Benign oncocytic adenoma</p>
          </list-item>
          <list-item>
            <p>Follicular thyroid cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Papillary thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Thyroid lymphoma</p>
          </list-item>
          <list-item>
            <p>Medullary thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Parathyroid neoplasms</p>
          </list-item>
          <list-item>
            <p>Anaplastic thyroid carcinoma</p>
          </list-item>
          <list-item>
            <p>Thyroiditis</p>
          </list-item>
          <list-item>
            <p>Metastatic disease</p>
          </list-item>
          <list-item>
            <p>Goiter</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131177.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Staging of oncocytic thyroid cancer utilizes the tumor, node, metastasis (TNM) system from the American Joint Committee on Cancer (AJCC), with specific criteria tailored for this subtype. T staging categorizes tumors based on size and local extension: T1 indicates tumors &#x02264;2 cm, T2 for those &#x0003e;2 cm but &#x02264;4 cm, T3 for tumors &#x0003e;4 cm or with extrathyroidal extension, and T4 for any tumor with significant invasion into adjacent structures.&#x000a0;N staging assesses regional lymph node involvement, where N0 indicates no nodal involvement, N1a involves level VI (ie, pretracheal and paratracheal) nodes, and N1b includes lateral neck nodes. M staging denotes distant metastasis, with M0 indicating no distant spread and M1 for distant metastasis.</p>
        <p>Age also influences the stage of&#x000a0;oncocytic thyroid malignancies. Patients 55 or older are classified under a different prognostic category, often leading to a higher stage classification due to their increased risk of aggressive disease. Accurate staging is essential for guiding treatment decisions and predicting outcomes in&#x000a0;oncocytic thyroid cancer.<xref ref-type="bibr" rid="article-131177.r12">[12]</xref></p>
      </sec>
      <sec id="article-131177.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of oncocytic carcinoma is influenced by various clinical, pathological, and socioeconomic factors, reflecting its relatively aggressive nature compared to other differentiated thyroid cancers. The 10-year survival rate for patients with oncocytic carcinoma can exceed 90%, especially when detected early and managed effectively.<xref ref-type="bibr" rid="article-131177.r24">[24]</xref> However, prognosis declines significantly for those with advanced disease or unfavorable characteristics.</p>
        <p>A key prognostic indicator is tumor size. Tumors larger than 4 cm (classified as T3 or T4) are associated with a higher risk of metastasis and recurrence. Additionally, extrathyroidal extension correlates with poorer outcomes, particularly when involving adjacent structures. Age is also a crucial prognostic factor. Patients diagnosed at age 55 or older face a higher risk of aggressive disease progression, often exacerbated by comorbidities and the effects of biological aging.</p>
        <p>Lymph node involvement is another critical consideration. Patients with regional lymph node metastases (ie, N1a or N1b) have increased recurrence risks and lower survival rates. Additionally, vascular invasion&#x02014;where cancer cells invade blood vessels&#x02014;significantly predicts poor prognosis and higher rates of distant metastasis.<xref ref-type="bibr" rid="article-131177.r7">[7]</xref> Long-term follow-up is essential due to the potential for late recurrence. The American Thyroid Association (ATA) risk stratification system is commonly used by clinicians postsurgery to predict disease recurrence and guide surveillance.<xref ref-type="bibr" rid="article-131177.r25">[25]</xref><xref ref-type="bibr" rid="article-131177.r5">[5]</xref></p>
        <p>Regular monitoring through ultrasound and serum thyroglobulin levels is vital for early detection of recurrence, which can improve management outcomes. While oncocytic carcinoma presents significant prognostic challenges, timely and personalized treatment approaches can improve outcomes.</p>
      </sec>
      <sec id="article-131177.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with oncocytic thyroid cancer can arise from both the disease and its treatment. A significant concern is local invasion, which may compress surrounding structures such as the trachea, esophagus, or recurrent laryngeal nerve. This compression can lead to symptoms, including difficulty swallowing, breathing problems, or hoarseness. Oncocytic carcinoma also tends to spread through the lymphatic system, resulting in swollen lymph nodes and potential surgical complications if lymph node dissection is necessary. Additionally, the disease can spread to distant sites, such as the lungs and bones, making management and prognosis more challenging.</p>
        <p>While often necessary, surgical intervention carries a risk for complications, including bleeding, infection, and damage to adjacent tissues or nerves. Patients may also experience long-term issues related to thyroid hormone management postthyroidectomy, including hypothyroidism and the need for lifelong hormone replacement therapy. The potential for the cancer to come back adds a psychological burden, requiring ongoing monitoring and follow-up, which can contribute to anxiety and uncertainty. Therefore, a comprehensive approach to management is essential to address these multifaceted complications associated with oncocytic thyroid carcinoma.</p>
      </sec>
      <sec id="article-131177.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Oncocytic carcinomas can be more aggressive than other differentiated types of thyroid carcinomas. The United States Preventive Services Task Force does not recommend routine screening methods for diagnosing thyroid neoplasms in the general asymptomatic population. However, patients with a family history of medullary thyroid carcinomas, multiple endocrine neoplasia, a personal history of thyroid cancer, familial adenomatous polyposis syndrome, or radiation exposure are at a higher risk of developing thyroid cancer. They should be educated about the importance of being vigilant for suspicious signs or symptoms. Timely evaluation of any such symptoms is critical to early diagnosis and treatment.&#x000a0;</p>
      </sec>
      <sec id="article-131177.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with oncocytic cell carcinoma requires a highly collaborative, interprofessional approach involving physicians, advanced practitioners, nurses, pharmacists, and other health professionals. Each team member plays a critical role in enhancing care coordination, patient safety, and team performance. Clinicians, such as endocrinologists, oncologists, and surgeons, must develop specialized skills in diagnosing and evaluating this rare thyroid cancer, including proficiency in interpreting imaging studies and understanding its distinct histopathological features. Given the complexity of oncocytic carcinoma, referrals to surgical specialists or oncologists are often necessary, particularly for patients with aggressive disease or high-risk characteristics. Advanced practitioners and nurses also play key roles in patient education, follow-up care, and monitoring for complications or recurrence.</p>
        <p>Ethical considerations and patient autonomy must guide all discussions about treatment options, ensuring that patients are fully informed about the risks and benefits of various approaches, including active surveillance or more aggressive interventions. Effective interprofessional communication is essential, with each team member clearly understanding their responsibilities in contributing specialized knowledge to optimize patient care. Pharmacists may be involved in managing medications and exploring new targeted therapies, while pathologists are critical in accurate diagnosis.</p>
        <p>Care coordination ensures seamless transitions from initial diagnosis through treatment and ongoing follow-up. Regular interprofessional meetings allow for shared decision-making and improved communication, minimizing errors and delays and enhancing patient safety and outcomes. Through this collaborative, patient-centered approach, healthcare professionals can address the unique challenges of oncocytic thyroid carcinoma, improving overall care quality and ensuring the best possible patient outcomes.</p>
      </sec>
      <sec id="article-131177.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131177&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131177">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/hurthle-cell-thyroid-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=131177">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131177/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131177">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-131177.s17">
        <fig id="article-131177.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Thyroid Carcinoma. High Power Magnification demonstrates tumor cells with deeply eosinophilic and granular cytoplasm, large nuclei with prominent nucleoli, and a complete loss of cell polarity. Librepath, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/wiki/File:Hurthle_cell_carcinoma_--_very_high_mag.jpg">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1200px-Hurthle_cell_carcinoma_--_very_high_mag" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-131177.s18">
        <title>References</title>
        <ref id="article-131177.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Bychkov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kakudo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>703</fpage>
            <page-range>703-718</page-range>
            <pub-id pub-id-type="pmid">36193717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McFadden</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Sadow</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Genetics, Diagnosis, and Management of H&#x000fc;rthle Cell Thyroid Neoplasms.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>696386</fpage>
            <pub-id pub-id-type="pmid">34177816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doerfler</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Nikitski</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Morariu</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ohori</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Chiosea</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Landau</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nikiforova</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Nikiforov</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manroa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Molecular alterations in H&#x000fc;rthle cell nodules and preoperative cancer risk.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2021</year>
            <month>Apr</month>
            <day>27</day>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>301</fpage>
            <page-range>301-309</page-range>
            <pub-id pub-id-type="pmid">33792557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kure</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Thyroid H&#x000fc;rthle Cell Carcinoma: Clinical, Pathological, and Molecular Features.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Dec</month>
            <day>23</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33374707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boucai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zafereo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Cancer: A Review.</article-title>
            <source>JAMA</source>
            <year>2024</year>
            <month>Feb</month>
            <day>06</day>
            <volume>331</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-435</page-range>
            <pub-id pub-id-type="pmid">38319329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganly</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Makarov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deraje</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Reznik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seshan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nanjangud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>LGT</given-names>
              </name>
              <name>
                <surname>Landa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Carrillo Albornoz</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nikiforov</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Umbricht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeiger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kebebew</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghossein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fagin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Integrated Genomic Analysis of H&#x000fc;rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.</article-title>
            <source>Cancer Cell</source>
            <year>2018</year>
            <month>Aug</month>
            <day>13</day>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-270.e5</page-range>
            <pub-id pub-id-type="pmid">30107176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Angell</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Krane</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>H&#x000fc;rthle cell lesions of the thyroid: Progress made and challenges remaining.</article-title>
            <source>Cancer Cytopathol</source>
            <year>2021</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>347</fpage>
            <page-range>347-362</page-range>
            <pub-id pub-id-type="pmid">33108684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fariduddin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <chapter-title>Hurthle Cell Thyroid Carcinoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">33760495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabra</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ghossein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>518</fpage>
            <page-range>518-24</page-range>
            <pub-id pub-id-type="pmid">26872102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Angell</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Babiarz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Blevins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Ghossein</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Harrell</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kloos</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>LiVolsi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Sadow</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Shanik</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Traweek</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Whitney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Ladenson</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.</article-title>
            <source>JAMA Surg</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>153</volume>
            <issue>9</issue>
            <fpage>817</fpage>
            <page-range>817-824</page-range>
            <pub-id pub-id-type="pmid">29799911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steward</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Carty</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sipos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Figge</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haugen</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Baloch</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Seethala</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Gooding</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Chiosea</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Gomes-Lima</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Folek</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Khawaja</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kundra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Mayson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Nga</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ngiam</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Nikiforova</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Poehls</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ringel</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nikiforov</surname>
                <given-names>YE</given-names>
              </name>
            </person-group>
            <article-title>Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.</article-title>
            <source>JAMA Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>204</fpage>
            <page-range>204-212</page-range>
            <pub-id pub-id-type="pmid">30419129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blomain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Busaidy</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Ehya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldner</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haymart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Iagaru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kandeel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lamonica</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Markovina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McIver</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raeburn</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Scheri</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sipos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cassara</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Darlow</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>925</fpage>
            <page-range>925-951</page-range>
            <pub-id pub-id-type="pmid">35948029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Habra</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Newbold</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Gianoukakis</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kiyota</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Krzyzanowska</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dutcus</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>de las Heras</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Feb</month>
            <day>12</day>
            <volume>372</volume>
            <issue>7</issue>
            <fpage>621</fpage>
            <page-range>621-30</page-range>
            <pub-id pub-id-type="pmid">25671254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nutting</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Jarzab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elisei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bastholt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de la Fouchardiere</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paschke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shong</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kappeler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pe&#x000f1;a</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moln&#x000e1;r</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>DECISION investigators</collab>
            </person-group>
            <article-title>Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Jul</month>
            <day>26</day>
            <volume>384</volume>
            <issue>9940</issue>
            <fpage>319</fpage>
            <page-range>319-28</page-range>
            <pub-id pub-id-type="pmid">24768112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laetsch</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Kummar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DuBois</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Lassen</surname>
                <given-names>UN</given-names>
              </name>
              <name>
                <surname>Demetri</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Nathenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doebele</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Farago</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Turpin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dowlati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Federman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El-Deiry</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Baik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deeken</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nagasubramanian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudzinski</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Meric-Bernstam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sohal</surname>
                <given-names>DPS</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Raez</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Hechtman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Benayed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuch</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Ebata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>22</day>
            <volume>378</volume>
            <issue>8</issue>
            <fpage>731</fpage>
            <page-range>731-739</page-range>
            <pub-id pub-id-type="pmid">29466156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dziadziuszko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krebs</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>de Braud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rolfo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karapetis</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Arkenau</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Otterson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>DSW</given-names>
              </name>
              <name>
                <surname>Prenen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Riehl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chow-Maneval</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Doebele</surname>
                <given-names>RC</given-names>
              </name>
              <collab>trial investigators</collab>
            </person-group>
            <article-title>Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>261</fpage>
            <page-range>261-270</page-range>
            <pub-id pub-id-type="pmid">31838015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirth</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lorch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Worden</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leboulleux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Godbert</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Owonikoko</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>DSW</given-names>
              </name>
              <name>
                <surname>Gautschi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de la Fouchardi&#x000e8;re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burkard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Laskin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kroiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medioni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Lakhani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ebata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heirich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kherani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Subbiah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Selpercatinib in <italic>RET</italic>-Altered Thyroid Cancers.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>27</day>
            <volume>383</volume>
            <issue>9</issue>
            <fpage>825</fpage>
            <page-range>825-835</page-range>
            <pub-id pub-id-type="pmid">32846061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>McCusker</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scilla</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gittens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arensmeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rolfo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>RET fusions in solid tumors.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>81</volume>
            <fpage>101911</fpage>
            <pub-id pub-id-type="pmid">31715421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oxnard</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>DSW</given-names>
              </name>
              <name>
                <surname>Loong</surname>
                <given-names>HHF</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gainor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCoach</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gautschi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Besse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Peled</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Barlesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cassier</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bazhenova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Braud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garralda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Velcheti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Satouchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pennell</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Reckamp</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Dy</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Falchook</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ebata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Olek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subbiah</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Selpercatinib in <italic>RET</italic> Fusion-Positive Non-Small-Cell Lung Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>27</day>
            <volume>383</volume>
            <issue>9</issue>
            <fpage>813</fpage>
            <page-range>813-824</page-range>
            <pub-id pub-id-type="pmid">32846060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marabelle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Di Giacomo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>De Jesus-Acosta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delord</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Geva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gottfried</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piha-Paul</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lopez-Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Frommer</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joe</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">31682550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuttle</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rondeau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NY</given-names>
              </name>
            </person-group>
            <article-title>A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer.</article-title>
            <source>Cancer Control</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-95</page-range>
            <pub-id pub-id-type="pmid">21451451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romesser</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Shaha</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sabra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Fagin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NY</given-names>
              </name>
            </person-group>
            <article-title>External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.</article-title>
            <source>J Surg Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>110</volume>
            <issue>4</issue>
            <fpage>375</fpage>
            <page-range>375-82</page-range>
            <pub-id pub-id-type="pmid">24961938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Servagi Vernat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalifa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Kammerer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faivre</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sio</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bar-Sela</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Salleron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thariat</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis.</article-title>
            <source>Cancers (Basel)</source>
            <year>2019</year>
            <month>Jun</month>
            <day>19</day>
            <volume>11</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31248183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humphreys</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Memeh</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Funkhouser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaghaiwalla</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors and survival analysis of Hurthle cell carcinoma: A&#x000a0;population-based study.</article-title>
            <source>Surgery</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>172</volume>
            <issue>5</issue>
            <fpage>1379</fpage>
            <page-range>1379-1384</page-range>
            <pub-id pub-id-type="pmid">36038373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131177.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haugen</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bible</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nikiforov</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Sawka</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuff</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Steward</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wartofsky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-133</page-range>
            <pub-id pub-id-type="pmid">26462967</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
